ConversationChristine ViauHead of Investor Relations Well, good morning, everyone. On behalf of BMO's executive team, it is my pleasure to welcome you to BMO's 2026 Investor Day. I'm Christine Viau, Head of Investor Relations. This year, I'll be celebrating my 30th anniversary with BMO, and 10 of those I've had the privilege of serving in Investor Relations. It's just so wonderful to see so many of you in the room today. Before we begin our formal program, I would like to recognize the home traditional terr ...

CALGARY, Alberta, March 30, 2026 (GLOBE NEWSWIRE) -- PrairieSky Royalty Ltd. ("PrairieSky") will release its Q1 2026 results on Monday, April 20, 2026 after markets close. The news release detailing PrairieSky’s Q1 2026 results will provide operating and financial information. Financial statements along with management’s discussion and analysis will be available on PrairieSky’s website at www.prairiesky.com and on SEDAR+ at www.sedarplus.ca. A conference call to discuss the results will be held for the inve ...

FDA assigned PDUFA target action date of September 27, 2026 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its New Drug Application (NDA) for relutrigine, for the treatment of SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). The FDA has set a ...

Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in study, which U.S. Food and Drug Administration (FDA) reiterated in October may serve as primary basis of approval under Accelerated Approval pathway Rolling submission of Biologics License Agreement (BLA) to FDA seeking ST-920 approval is in progress Transitioned to a clinical-stage neurolo ...

Progressing vision to expand the reach of targeted radiopharmaceuticals to large patient populationsAnticipating multiple milestones in the next 12 months, including initiation of Phase 1b clinical trial of AKY-2519 in mid-2026 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform t ...

HOUSTON, TX, March 30, 2026 (GLOBE NEWSWIRE) -- Prairie Operating Co. (Nasdaq: PROP) (the “Company” or “Prairie”), an independent energy company engaged in the development and acquisition of oil and natural gas resources in the Denver-Julesburg (DJ) Basin – today announced it will release its fiscal year 2025 financial and operating results after market close on March 30, 2026. The Company will host a conference call and webcast the following day at 8:30 AM Eastern Time (7:30 AM Central Time) to review the ...

PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat populationPhase 1b data demonstrate endoscopic improvement, with a 47.5% reduction in SES-CD score and 40% of patients achieving endoscopic response and 40% of patients achieving endoscopic remissionPharmacokinetic and pharmacodynamic data from ileal tissue and plasma support once-daily oral dosing for Crohn’s disease showing IC90 coverage, with correlation to accepted ...

WESTLAKE, Texas, March 30, 2026 (GLOBE NEWSWIRE) -- Goosehead Insurance, Inc. (“Goosehead” or the “Company”) (NASDAQ: GSHD), a rapidly growing independent personal lines insurance agency, today announced the appointment of Martin Thornthwaite as General Counsel and Corporate Secretary, effective March 30, 2026. Mr. Thornthwaite most recently served as Senior Vice President and Associate General Counsel at RealPage, Inc., where he was responsible for overseeing complex commercial and consumer litigation, reg ...

Q4 and FY Revenue of $9.2 million and $38.7 millionQ4 and FY Income from Continuing Operations of $22.8 million and $25.0 million (benefiting from a one-time, non-cash tax-related accounting adjustment)Q4 and FY Thyroid volume year-over-year increase of 11% and 13%Q4 and FY Thyroid revenue year-over-year increase of 14% and 21% PARSIPPANY, NJ, March 30, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX: IDXG) today announced financial results for the fourth quarter a ...

ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA Tanruprubart MAA Filed in Europe with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); U.S./European FORWARD Study Data Expected to Support Planned BLA Submission in 2026 ANX1502 Advancing as First Oral C1 Inhibitor for Autoimmune Disease; Proof-of-Concept (POC) Data Anticipated in 2026 Strong Balance Sheet wi ...